Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

Biotron identifies new compounds in Zika program, signs agreement with NIAID

Aug. 24, 2016

AstraZeneca discloses potent capsid-binding human rhinovirus inhibitor AZN-001

Aug. 23, 2016

New phase II trial explores safety and immunogenicity of TSI-GSD-210 for Western equine encephalitis

Aug. 22, 2016

Shionogi initiates phase III trial of S-649266 to treat carbapenem-resistant Gram-negative bacteria

Aug. 22, 2016

PATH initiates phase I trial of MCV-5 meningococcal conjugate vaccine

Aug. 22, 2016

Chinese clinical trial authorization for TaiGen's furaprevir

Aug. 19, 2016

NIAID funding supports testing of Kineta's broad-spectrum antivirals in preclinical Zika models

Aug. 19, 2016

Xenetic Biosciences starts collaboration with Excivion to develop Zika vaccine

Aug. 19, 2016

Quidel obtains FDA clearance to market Solana Trichomonas assay

Aug. 18, 2016

FDA grants orphan drug designation to Pulmatrix's PUR-1900

Aug. 18, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 6, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...